Behind every biotech is a stack of software: the systems that run the lab, manage the trial, keep the company compliant, and turn data into decisions. This layer rarely makes headlines, but it is where an enormous amount of value, and increasingly, AI, now lives. Here are the platforms biotech and pharma actually run on in 2026, grouped by what they do, plus the trend reshaping all of them at once.
Why the software layer matters
Modern drug development generates staggering amounts of data and operates under intense regulatory scrutiny, which makes purpose-built, compliant software essential rather than optional. The life-science software market is large and growing, and it has produced some of the most durable businesses in the whole sector, because once a company standardizes on a platform for its regulated workflows, switching is painful and rare. That stickiness is why these companies are so valuable, and why the category is worth understanding even if you never write a line of code.
The life-science cloud and R&D platforms
At the center of the industry sit the platforms that run core operations.
- Veeva Systems is the dominant force, a life-sciences cloud spanning clinical, regulatory, quality, safety, and commercial operations, used by well over a thousand companies from the largest pharmas to emerging biotechs. Its scale is immense, and it is now rolling out industry-specific AI agents across its platform.
- Benchling is the leading R&D platform, unifying the electronic lab notebook, sample management, and molecular biology workflows that early biotechs otherwise cobble together from spreadsheets and paper. It serves well over a thousand biotech customers and has moved aggressively to embed AI models directly into the research workflow.
- Dotmatics and specialist laboratory information management systems such as LabWare round out the R&D and lab-data layer.
Clinical trial software
Running a trial is a software-intensive undertaking, and a distinct set of platforms serves it.
- Medidata (owned by Dassault Systèmes) is one of the largest clinical trial technology companies, with its Rave electronic data capture system an industry standard for large global studies.
- Oracle has a long history in clinical data management and drug safety systems, and Veeva‘s clinical suite brings trial management onto its unified platform.
- For smaller and emerging biotechs, more accessible platforms such as Castor, Medrio, and Medable, along with decentralized-trial specialists like Curebase, offer faster, lower-cost options suited to early-phase studies.
Quality, regulatory, and safety
Compliance is non-negotiable in this industry, and specialized software manages it. Veeva‘s quality and regulatory suites are widely used, MasterControl is a long-standing leader in quality management, and Qualio serves emerging biotech and device companies that want modern quality management without enterprise complexity. In drug safety and pharmacovigilance, providers such as ArisGlobal manage the intake and reporting of adverse events, increasingly with AI assistance. This unglamorous category is essential: a compliance failure can halt a program entirely.
Real-world data and analytics
A newer, fast-growing layer turns healthcare data into insight for research and commercialization. Companies such as Komodo Health, Aetion, Truveta, and Flatiron Health (a leader in oncology real-world data) build large, structured datasets and analytics that inform trial design, market access, and drug development. As drug developers lean harder on real-world evidence, this category has become strategically central, blurring the line between a software vendor and a data partner.
The AI agent wave
The defining trend of 2026 is the arrival of AI throughout this stack. The major platforms are embedding AI agents and copilots directly into their products, to draft regulatory documents, speed content review, summarize literature, assist clinical operations, and reduce the manual work that fills scientists’ and operators’ days. The consistent lesson emerging from early adoption is that the bottleneck is rarely the AI models themselves but the quality and structure of the underlying data, which is exactly why the platforms that own clean, structured data are best positioned to deliver real AI value. This is quietly reshaping the competitive landscape, favoring the incumbents with the deepest, best-organized data.
The patient-facing edge
Alongside the software that runs biotech sits the digital health layer that touches patients and clinicians directly, telehealth, remote monitoring, and a booming category of AI tools that automate clinical documentation. While distinct from the R&D and trial software above, this layer increasingly connects to it, as patient-generated data flows back into research and as the same AI advances ripple across both worlds.
What to look for
Evaluating these platforms comes down to a few questions. How deeply is the product embedded in regulated, mission-critical workflows, which determines how sticky and defensible it is? How much recurring revenue does it earn, and how much of the customer’s operation runs through it? And, increasingly, does the company own the clean, structured data that makes its AI features genuinely useful rather than superficial? The strongest platforms combine deep workflow integration, high switching costs, and a real data advantage.
The bigger picture
The software layer is where much of biotech’s efficiency, and increasingly its intelligence, now lives. As AI moves from pilot to production across this stack, the platforms that run the industry are becoming even more central to how drugs get discovered, tested, and brought to market. This snapshot captures the notable players, but the category is deep and evolving quickly, especially at the AI frontier.
Build versus buy, and why the incumbents are hard to dislodge
A question every biotech faces is whether to build software internally or buy it from these vendors, and the answer, overwhelmingly, is to buy. Building and, crucially, validating compliant software for regulated workflows is enormously expensive and slow, and it is not where a drug developer’s competitive advantage lies. So the industry has consolidated around a set of specialized platforms, which is exactly why those platforms are so valuable and so durable. Once a company standardizes on a system for its clinical, regulatory, or quality operations, switching means migrating critical data, revalidating processes, and retraining teams, a painful, risky undertaking that companies avoid unless they must. This stickiness gives the incumbents a powerful moat and helps explain why the leaders in each category tend to stay the leaders. It also shapes where the competitive action is: rather than displacing entrenched platforms head-on, many newer vendors target the segments the giants serve less well, particularly smaller and emerging biotechs that need compliant capability without enterprise cost and complexity, and CDMOs, device makers, and diagnostics labs whose workflows differ from big pharma’s. For a buyer, the practical lesson is to choose carefully and for the long term, because you are not buying a tool you will casually swap out; you are choosing the system your regulated operations will run on for years, and the cost of choosing badly is high.
The bottom line
The software layer is easy to overlook because it does not make headlines the way a new drug does, but it is where a great deal of biotech’s efficiency, compliance, and increasingly its intelligence now lives. The industry runs on a set of specialized, sticky platforms, anchored by the life-science cloud and R&D leaders and extending through clinical, quality, safety, and data tools, and those platforms are becoming more central as AI moves from pilot to production across them. For anyone in the field, whether choosing tools for your own company, investing in the space, or simply trying to understand how modern biotech operates, the key takeaways are that these platforms are durable because switching is so costly, that the AI advantage flows to whoever owns the cleanest data, and that the fastest-growing opportunities are in serving the smaller biotechs and adjacent players the giants historically underserved. The snapshot here captures the notable names, but the category is deep and moving quickly, especially at the AI frontier, so it rewards ongoing attention.
For the full, regularly updated map of digital health and biotech software platforms, browse the BioMed Nexus digital health and biotech SaaS directory, and to follow the launches, funding, and AI developments reshaping the space, the daily brief covers it as it happens.
Frequently asked questions
What software do biotech and pharma companies use?
Core platforms include Veeva Systems for clinical, regulatory, quality and commercial operations, and Benchling for R&D and lab data. Clinical trials run on tools like Medidata, Oracle and Veeva; quality and safety on MasterControl, Qualio and ArisGlobal; and real-world data on Komodo Health, Aetion, Truveta and Flatiron Health.
What is the biggest life-science software company?
Veeva Systems is the dominant life-science software company, providing a cloud platform that spans clinical, regulatory, quality, safety and commercial operations for well over a thousand pharma, biotech and device customers. It reported multi-billion-dollar annual revenue and is rolling out industry-specific AI agents across its products.
How is AI changing biotech software in 2026?
The major platforms are embedding AI agents and copilots to draft regulatory documents, speed content review, summarize literature and assist clinical operations. The key lesson from early adoption is that clean, structured data, not the AI models themselves, is the main bottleneck, which favors platforms that already own well-organized data.
